Program
CLDN6 CAR-T
Its studies are mostly in Testicular Neoplasms · Testicular Germ Cell Tumor, led by BioNTech.
Furthest: phase 2, since Apr 16, 20252 company-led studies, 1 open or runningNext primary completion: Aug 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioNTech | 21 open or running | phase 2since Apr 16, 2025 | Jul 28, 2020 | Aug 2028phase 1 · NCT04503278 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 28, 2020First study: phase 1 study in Testicular NeoplasmsFirst studyNCT04503278 · 214 enrolled · Australia, Germany, Netherlands and more
- Apr 16, 2025Phase 2 study in Testicular Germ Cell TumorNCT06940804
Ahead
- Aug 2028Primary completion: phase 1 study in Testicular NeoplasmsNCT04503278
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06940804Testicular Germ Cell Tumor | 2 | Withdrawn | Jun 2042 | 0 |
| NCT04503278Testicular Neoplasms · Australia, Germany, Netherlands and more | 1 | Active, not recruiting | Aug 2028 | 214 |
How it is read
Names in the registry
- “CLDN6 CAR-T”, 2 entries
Conditions, from the studies’ own filings
- Testicular Neoplasms, 1 study
- Testicular Germ Cell Tumor, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.